Hansoh Pharmaceutical's (HKG:3692) obtained clinical trial approval for its HS-10541 tablets from China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.
Shares of the pharma firm were down over 1% in Thursday afternoon trading.
The trial will study the drug for the treatment of patients with KRAS G12C-mutated advanced solid tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments